Adam Castaño

BridgeBio (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index5.5kcitations85works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(62), Parathyroid Disorders and Treatments(36), Medical Imaging and Pathology Studies(15), Sarcoidosis and Beryllium Toxicity Research(13), Peptidase Inhibition and Analysis(9)

Publications84 total

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
JAMA Cardiology·2025Open Access
Abstract 4368295: Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results From the ATTRibute-CM Study
Circulation·2025
Abstract 4365761: Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status
Circulation·2025
Abstract 4363872: Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Circulation·2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM
Journal of the American College of Cardiology·2025· 3 citedOpen Access
Acoramidis Improves Serum Transthyretin Levels in Patients With Wild-type or Variant Transthyretin Amyloid Cardiomyopathy - Results From ATTRibute-CM
Journal of Nuclear Cardiology·2025
Acoramidis-Mediated Improvement in NT-proBNP at Month 30 Compared With Placebo in Patients With ATTR-CM: Results From the ATTRibute-CM Study
Journal of Nuclear Cardiology·2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
Journal of the American College of Cardiology·2025· 21 citedOpen Access
PRIMARY ENDPOINT EFFICACY RESULTS IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED SENSITIVITY ANALYSES ADDRESSED TAFAMIDIS USE
Journal of the American College of Cardiology·2025· 1 citedOpen Access
ROBUSTNESS OF PRIMARY ENDPOINT EFFICACY RESULTS WITH ACORAMIDIS IN ATTR-CM IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED NT-PROBNP SENSITIVITY ANALYSES
Journal of the American College of Cardiology·2025Open Access
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Journal of the American College of Cardiology·2025· 30 citedOpen Access
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy
Circulation Heart Failure·2024· 15 citedOpen Access
Rationale & Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial: Early Detection Using Cardiac Radionuclide Imaging
Journal of Nuclear Cardiology·2024· 11 cited
E-051 Chronic subdural hematoma evacuation and middle meningeal artery embolization in a single setting in the hybrid operating room: a unique single center experience
2024Open Access
Rationale and Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial PC110 (#190)
2024· 1 cited
EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy
Journal of Cardiac Failure·2023· 6 citedOpen Access
Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population
The American Journal of Cardiology·2022· 13 citedOpen Access
Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction
European Heart Journal·2021· 4 citedOpen Access
A Virtual Cardiovascular Care Program for Prevention of Heart Failure Readmissions in a Skilled Nursing Facility Population: Retrospective Analysis
JMIR Cardio·2021· 9 citedOpen Access
A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy
Nature Communications·2021· 103 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Mathew S. Maurer(30), Sabahat Bokhari(21), David L. Narotsky(7), Daniel P. Judge(7), Ahmad Masri(7), Julian D. Gillmore(6), Matthew J. Maurer(5), Frederick L. Ruberg(5), Rachelle Morgenstern(5), Tamim Nazif(5), Susheel Kodali(5), Rebecca T. Hahn(5), Ted Pozniakoff(5), Stephen Helmke(5), Julissa Alvarez(5), Hannah Rosenblum(5), Prem Soman(5), Marianna Bruno(5), Jean‐François Tamby(5), Martha Grogan(4)